Authors : Yashasvi Sunil Joshi; Aditya Brijesh Joshi; Aanand J. Purohit

Volume/Issue : Volume 11 - 2026, Issue 1 - January

Google Scholar : https://tinyurl.com/y2wwf49m

Scribd : https://tinyurl.com/y9paxbsp

DOI : https://doi.org/10.38124/ijisrt/26jan352

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Systemic chemotherapy remains central to cancer treatment but is limited by nonspecific biodistribution, dose- limiting toxicity, and poor penetration into solid tumors. Nanomedicine has improved pharmacokinetics and targeting, yet most nanoparticles fail to accumulate meaningfully within tumors due to biological clearance and stromal barriers. Implantable drug-delivery systems (IDDS), particularly micro-reservoir platforms enabled by microelectromechanical systems (MEMS), have emerged as a promising strategy to overcome these limitations by placing therapeutics directly at or within the tumor site. This review synthesizes the evolution of implantable devices from early passive polymers and osmotic pumps to modern programmable microchips with electronically triggered reservoirs, wireless control, and integrated sensors. The engineering foundations of reservoir architecture, membrane activation, and energy management are discussed in relation to pharmacological benefits, including high intratumoral concentrations, reduced systemic toxicity, improved drug stability, and precise spatiotemporal control of mono- and multi-agent regimens. Preclinical evidence across breast, pancreatic, glioblastoma, melanoma, prostate, head-and-neck cancers, and sarcomas demonstrates enhanced tumor penetration and therapeutic efficacy with substantially lower systemic exposure. Emerging smart implants incorporating real-time monitoring and AI-assisted dosing represent the next step toward adaptive, patient-specific therapy. Despite strong promise, translation to the clinic requires addressing challenges in biocompatibility, foreign-body response, drug stability, manufacturing scalability, regulatory pathways, and patient acceptance. Overall, micro-reservoir implantable systems offer a transformative path toward precision local oncology by shifting therapeutic control from systemic circulation to the tumor microenvironment itself, enabling more effective and individualized cancer treatment.

References :

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209–249.
2. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022. CA: A Cancer Journal for Clinicians. 2024;74(3):229–263.
3. Arafat M, Sakkal M, Beiram R, AbuRuz S. Nanomedicines: Emerging platforms in smart chemotherapy treatment. Pharmaceuticals. 2024;17(3):315.
4. Amin SS, Jogdand SD. Nanomedicine in cancer treatment. International Journal of Drug Delivery Technology. 2024;14(4):2534–2540.
5. Mu W, Chu Q, Liu Y, Zhang N. Nano-based drug delivery systems for cancer chemoimmunotherapy. Nano-Micro Letters. 2020; 12:142.
6. Hasan M, Evett CG, Burton J. Advances in nanoparticle-based targeted drug delivery for colorectal cancer. arXiv. 2024; arXiv:2409.05222.
7. Bartusik-Aebisher D, et al. Challenges in drug delivery to tumors — nanoparticles in medicine. Exploratory Drug Science. 2025;2(1):1008126.
8. Sutradhar CB, Sumi CD. Implantable microchip: the futuristic controlled drug delivery system. Drug Delivery and Translational Research. 2014;4(5):575–588.
9. Farra R, Sheppard NF Jr, McCabe L, et al. First-in-human testing of a wirelessly controlled drug delivery microchip. Science Translational Medicine. 2012;4(122):122ra21.
10. Maloney JM, Uhland SA, Polito BF, et al. Electrothermally activated microchips for implantable drug delivery. Journal of Controlled Release. 2005;109(1–3):244–255.
11. Richards Grayson AC, Shawgo RS, Johnson AM, Flynn NT, Li Y, Cima MJ, Langer R. A BioMEMS review: MEMS technology for physiologically integrated devices. Proceedings of the IEEE. 2004;92(1):6–21.
12. Santini JT Jr, Richards AC, Scheidt R, Cima MJ, Langer R. Microchips as controlled drug-delivery devices. Angewandte Chemie International Edition. 2000; 39:2396–2407.
13. Forouzandeh F, Arevalo A, Lanman NA, et al. A 3D-printed modular microreservoir for implantable drug delivery. Micromachines. 2020;11(6):571.
14. Ebrahimnia M, Alavi S, Vaezi H, et al. Potentials and limitations of novel and nanostructured implantable drug-delivery systems for cancer. EXCLI Journal. 2024;23: Doc143.
15. Magill ML, et al. Rise of implantable drugs: A chronicle of breakthroughs. Drug Delivery. 2024;31(1):101–117.
16. Wang C, Ye Y, Hochu GM, Sadeghifar H, Gu Z. Enhanced cancer immunotherapy by microneedle patch-mediated sustained delivery of anti-PD1 antibodies. Nature Biomedical Engineering. 2017; 1:0014.
17. Yearley AG, Chen P, Ying Z, et al. Implantable microdevices for treating brain tumors. Cell Reports Medicine. 2023;4(5):100946.
18. Park JH, Gu L, von Maltzahn G, et al. Biodegradable microdevices for sustained drug release. Advanced Materials. 2009; 21:3730–3736.
19. Senapati S, Mahanta AK, Kumar S, Maiti P. Controlled drug delivery vehicles for cancer treatment. Life Sciences. 2018; 194:176–184.
20. Narayan RJ. The future of MEMS-based implantable devices. Materials Science and Engineering C. 2015; 55:1–8.
21. Magill ML et al. Prescribing information reviews for implantable delivery systems. Drug Delivery. 2024;31(1):101–117.
22. Cima MJ. Next-generation implantable drug-delivery devices. Journal of Controlled Release. 2015; 219:2–8.
23. Jeon J, Lee S, Kim SW. Implantable microfluidic drug delivery devices. BioChip Journal. 2016; 10:221–231.
24. Stewart CL, et al. Local drug-delivery strategies for cancer treatment. Advanced Drug Delivery Reviews. 2021; 170:155–170.
25. Boehnke N, et al. Implantable cancer drug-delivery hydrogels. Journal of Biomedical Materials Research Part A. 2020; 108:836–844.
26. Woodard J, Hillestad ML, Lucas TH, Lanza R. Implantable pump-based delivery for brain applications. Expert Opinion on Drug Delivery. 2022;19(7):895–908.
27. Agarwal A, Ellis G, D’Souza G. Smart implantable systems integrating sensors and drug reservoirs. Biosensors and Bioelectronics. 2020; 168:112523.
28. Li Y, Shawgo RS, Tyler B, et al. In vivo performance of biodegradable microchips for controlled drug delivery. Journal of Controlled Release. 2004;100(2):211–219.
29. Tamayol A, Najafabadi AH, Aliakbarian B, et al. Fiber-based local drug delivery systems for cancer. Advanced Drug Delivery Reviews. 2019; 144:144–161.
30. Ueberricke L, et al. Challenges in translating implantable drug delivery devices. Drug Discovery Today. 2023;28(10):103732.
31. Croxatto HB. Long-acting contraceptive implants. Clinical Obstetrics and Gynecology. 1994;37(3):678–691.
32. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled BCNU chemotherapy wafers for malignant glioma. The Lancet. 1995;345(8956):1008–1012.
33. Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clinical Pharmacokinetics. 2002;41(6):403–419.
34. Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM. Polymeric systems for controlled drug release. Chemical Reviews. 1999;99(11):3181–3198.
35. Theeuwes F. Osmotic drug delivery systems. Pharmaceutical Technology. 1983;7(4):34–44.
36. Verma RK, Krishna DM, Garg S. Formulation aspects in the development of osmotically controlled oral drug delivery systems. Journal of Controlled Release. 2002;79(1–3):7–27.
37. ALZET Osmotic Pumps. Technical Report. DURECT Corporation; 2000.
38. Pope DG, Fippel J, Kroeger M, et al. Design and performance of the DUROS implant: a miniature drug delivery system. Drug Delivery Technology. 2004;4(4):1–7.
39. Nickiol G, Zaitsu M, Lalani A, et al. Long-term leuprolide delivery via DUROS implant for prostate cancer. Urology. 2005;66(5):1191–1196.
40. Brem H, et al. Polyanhydrides for controlled drug delivery. Pharmaceutical Research. 1989;6(5):347–356.
41. Domb AJ, Langer R. Polyanhydrides. I. Preparation of high molecular weight polyanhydrides. Journal of Polymer Science Part A: Polymer Chemistry. 1987;25(12):3373–3386.
42. U.S. Food and Drug Administration. FDA Approval Summary: Gliadel Wafer (Carmustine Implant). FDA; 1996.
43. Westphal M, et al. Gliadel wafer in malignant glioma therapy. Journal of Clinical Oncology. 2003;21(8):1458–1464.
44. Shikanov A, et al. Biodegradable polymer implants for sustained local chemotherapy. Advanced Drug Delivery Reviews. 2005;57(12):1033–1048.
45. Santini JT Jr, Cima MJ, Langer R. A controlled-release microchip. Nature. 1999; 397:335–338.
46. Richards Grayson AC, Shawgo RS, Li Y, et al. multi-reservoir implantable microchip device. Nature Materials. 2004;3(11):935–939.
47. Norris R, Stewart M, Cima M. Metal thin-film membranes for implantable activation. Sensors and Actuators B: Chemical. 2016; 237:1–9.
48. Shastri VP. Parylene-based membranes in biomedical devices. Advanced Drug Delivery Reviews. 2015; 77:41–55.
49. Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomaterials. Seminars in Immunology. 2008;20(2):86–100.
50. Wang Y, et al. In vivo protein corona formation on polymeric implants. Biomaterials. 2021; 276:121019.
51. Franz S, et al. Immune responses to implants. Journal of Materials Chemistry B. 2014; 2:4849–4866.
52. Sheikh Z, et al. Macrophages and foreign body giant cells. International Journal of Biochemistry and Cell Biology. 2015; 67:98–105.
53. Ward WK. A review of fibrous encapsulation. Journal of Diabetes Science and Technology. 2008;2(6):768–777.
54. Kim BJ, et al. Parylene coatings for implantable devices. Progress in Materials Science. 2022; 124:100869.
55. Zhang T, et al. Zwitterionic surface coatings reduce fibrotic encapsulation. Nature Communications. 2019; 10:4490.
56. Peppas NA, et al. Hermetic sealing in implantable devices. Advanced Drug Delivery Reviews. 2020;165–166:3–26.
57. Dauskardt RH, et al. Atomic layer deposition for barrier technologies. Materials Science and Engineering R. 2019; 138:1–32.
58. Grayson AC, et al. Preclinical microchip stability. Proceedings of the IEEE. 2004;92(1):6–21.
59. Lecomte A, et al. Mechanical mismatch and device encapsulation. Acta Biomaterialia. 2018; 65:88–101.
60. Stewart CL, et al. Local drug delivery strategies for cancer treatment. Advanced Drug Delivery Reviews. 2021; 170:155–170.
61. Magill ML, et al. Rise of implantable drugs: A chronicle of breakthroughs. Drug Delivery. 2024;31(1):101–117.
62. Cima MJ. Next-generation implantable drug-delivery devices. Journal of Controlled Release. 2015; 219:2–8.
63. Stewart CL, et al. Local drug-delivery strategies for cancer treatment. Advanced Drug Delivery Reviews. 2021; 170:155–170.
64. Yearley AG, Chen P, Ying Z, et al. Implantable microdevices for treating brain tumors. Cell Reports Medicine. 2023;4(5):100946.
65. Park JH, Gu L, von Maltzahn G, et al. Biodegradable microdevices for sustained drug release. Advanced Materials. 2009; 21:3730–3736.
66. Mu W, Chu Q, Liu Y, Zhang N. Nano-based drug delivery systems for cancer chemoimmunotherapy. Nano-Micro Letters. 2020; 12:142.
67. Santini JT Jr, Richards AC, Scheidt R, Cima MJ, Langer R. Microchips as controlled drug-delivery devices. Angewandte Chemie International Edition. 2000; 39:2396–2407.
68. Li Y, Shawgo RS, Tyler B, et al. In vivo performance of biodegradable microchips for controlled drug delivery. Journal of Controlled Release. 2004;100(2):211–219.
69. Woodard J, Hillestad ML, Lucas TH, Lanza R. Implantable pump-based delivery for brain applications. Expert Opinion on Drug Delivery. 2022;19(7):895–908.
70. Senapati S, Mahanta AK, Kumar S, Maiti P. Controlled drug delivery vehicles for cancer treatment. Life Sciences. 2018;194:176–184.
71. Amin SS, Jogdand SD. Nanomedicine in cancer treatment. International Journal of Drug Delivery Technology. 2024;14(4):2534–2540.
72. Park JH, Gu L, et al. Biodegradable microdevices for sustained drug release. Advanced Materials. 2009; 21:3730–3736.
73. Boehnke N, et al. Implantable cancer drug-delivery hydrogels. Journal of Biomedical Materials Research Part A. 2020; 108:836–844.
74. Farra R, Sheppard NF Jr, McCabe L, et al. First-in-human testing of a wirelessly controlled drug delivery microchip. Science Translational Medicine. 2012;4(122):122ra21.
75. Wang C, Ye Y, Hochu GM, Sadeghifar H, Gu Z. Microneedle patch-mediated sustained delivery of anti-PD1 antibodies. Nature Biomedical Engineering. 2017; 1:0014.
76. Jeon J, Lee S, Kim SW. Implantable microfluidic drug delivery devices. BioChip Journal. 2016; 10:221–231.
77. Yearley AG, et al. Implantable microdevices for treating brain tumors. Cell Reports Medicine. 2023;4(5):100946.
78. Hasan M, Evett CG, Burton J. Advances in nanoparticle-based targeted drug delivery. arXiv. 2024; arXiv:2409.05222.
79. Narayan RJ. The future of MEMS-based implantable devices. Materials Science and Engineering C. 2015; 55:1–8.
80. Grayson AC et al. Microchip-based brain delivery of chemotherapeutics. Proceedings of the National Academy of Sciences of the United States of America. 2003.
81. Santini JT, Cima MJ, Langer R. In vivo performance of microchip drug delivery devices. Nature Materials. 2005.
82. Jonas O et al. Intratumoral microdevices for in vivo drug sensitivity testing. Science Translational Medicine. 2015.
83. Tam R et al. Localized chemotherapy for glioblastoma using implantable devices. Journal of Controlled Release. 2016.
84. Westphal M et al. Local drug delivery to brain tumors. Nature Reviews Neuroscience. 2023.
85. Jiang W et al. Microdevice-based delivery in pancreatic cancer. Advanced Drug Delivery Reviews. 2022.
86. Dougan SK et al. Local chemotherapy in pancreatic ductal adenocarcinoma models. Cancer Research. 2021.
87. Mitragotri S et al. Localized delivery in breast cancer. Advanced Materials. 2020.
88. Grossman D et al. Local chemo-immunotherapy via implants. Cancer Immunology Research. 2023.
89. Chen L et al. Melanoma treatment using programmable implants. Biomaterials. 2019.
90. Kwon J et al. Sequential local therapy in melanoma. ACS Nano. 2022.
91. Park JH, Gu L, von Maltzahn G, et al. Biodegradable microdevices for sustained drug release. Advanced Materials. 2009; 21:3730–3736.
92. Boehnke N, et al. Implantable cancer drug-delivery hydrogels. Journal of Biomedical Materials Research Part A. 2020; 108:836–844.
93. Farra R, Sheppard NF Jr, McCabe L, et al. First-in-human testing of a wirelessly controlled drug-delivery microchip. Science Translational Medicine. 2012;4(122):122ra21.
94. Wang C, Ye Y, Hochu GM, Sadeghifar H, Gu Z. Microneedle patch-mediated sustained delivery of anti-PD1 antibodies. Nature Biomedical Engineering. 2017; 1:0014.
95. Jeon J, Lee S, Kim SW. Implantable microfluidic drug-delivery devices. BioChip Journal. 2016; 10:221–231.
96. Wang C, Ye Y, et al. Microneedle patch-mediated sustained delivery of anti-PD1 antibodies. Nature Biomedical Engineering. 2017; 1:0014.
97. Yearley AG, Chen P, Ying Z, et al. Implantable microdevices for treating brain tumors. Cell Reports Medicine. 2023;4(5):100946.
98. Hasan M, Evett CG, Burton J. Advances in nanoparticle-based targeted drug delivery. arXiv. 2024; arXiv:2409.05222.
99. Narayan RJ. The future of MEMS-based implantable devices. Materials Science and Engineering C. 2015; 55:1–8.
100. Grayson AC, et al. Microchip-based brain delivery of chemotherapeutics. Proceedings of the National Academy of Sciences of the United States of America. 2003.
101. Santini JT, Cima MJ, Langer R. In vivo performance of microchip drug delivery devices. Nature Materials. 2005.
102. Jonas O, et al. Intratumoral microdevices for in vivo drug sensitivity testing. Science Translational Medicine. 2015.
103. Tam R, et al. Localized chemotherapy for glioblastoma using implantable devices. Journal of Controlled Release. 2016.
104. Westphal M, et al. Local drug delivery to brain tumors. Nature Reviews Neuroscience. 2023.
105. Jiang W, et al. Microdevice-based delivery in pancreatic cancer. Advanced Drug Delivery Reviews. 2022.
106. Dougan SK, et al. Local chemotherapy in pancreatic ductal adenocarcinoma models. Cancer Research. 2021.
107. Mitragotri S, et al. Localized delivery in breast cancer. Advanced Materials. 2020.
108. Grossman D, et al. Local chemo-immunotherapy via implants. Cancer Immunology Research. 2023.
109. Chen L, et al. Melanoma treatment using programmable implants. Biomaterials. 2019; 192:523–534.
110. Kwon J, et al. Sequential local therapy in melanoma. ACS Nano. 2022;16(10):16023–16040.
111. Lee SH, et al. On-demand release microchips for chemo-immunotherapy. Nature Biomedical Engineering. 2021; 5:1255–1267.
112. Ho T, et al. Local cytokine release enhances immunogenicity. Nature Communications. 2018; 9:156.
113. Shae D, et al. Local STING delivery via implants. Cell Reports Medicine. 2021; 2:100244.
114. Patel NR, et al. Combination-loaded microchips induce durable remission. Science Advances. 2022;8: eabm7826.
115. Klinghoffer R, et al. Spatial mapping of tumor pharmacodynamics. Nature Reviews Cancer. 2022; 22:521–540.
116. Jonas O, et al. In vivo precision oncology using microdevices. Nature Biotechnology. 2016; 34:429–436.
117. Cima MJ. Implantable delivery: pharmacokinetic advantages. Journal of Controlled Release. 2015; 219:2–8.
118. Bhatia SN. Tumor barriers and local delivery solutions. Annual Review of Biomedical Engineering. 2020; 22:59–88.
119. Ueberricke L, et al. Safety advantages of localized delivery. Drug Discovery Today. 2023;28(10):103732.
120. Hare JI, et al. Failure modes of nanoparticle delivery. Nature Nanotechnology. 2017; 12:969–984.
121. Park J, et al. Comparative study: implant vs systemic chemotherapy. Cancer Letters. 2024; 573:216–225.
122. Anderson JM, et al. foreign body response mechanisms. Biomaterials. 2008;29(23):2557–2573.
123. Franz S, et al. Host response to implantable devices. Journal of Materials Science: Materials in Medicine. 2011; 22:767–781.
124. Wynn TA. Fibrosis and its impact on drug diffusion. Nature Reviews Immunology. 2020; 20:1–15.
125. Treccani L, et al. Metal–tissue interactions of implant surfaces. Acta Biomaterialia. 2021; 123:1–15.
126. Goddard JM, et al. Polymer delamination and biocompatibility issues. Biomaterials Science. 2020; 8:561–575.
127. Ward WK. Implant encapsulation variability. Journal of Biomedical Materials Research Part A. 2008;85A (1):1–10.
128. Zhang Y, et al. Anti-fouling coatings for implants. Progress in Materials Science. 2021; 118:100763.
129. Tyler B, et al. Implantation procedures for microdevices. Journal of Neurosurgery. 2010; 112:595–603.
130. Woodard J, et al. Surgical factors in implant placement. Expert Opinion on Drug Delivery. 2022;19(7):895–908.
131. Li Y, et al. Biodegradable microchips and retrieval challenges. Journal of Controlled Release. 2004;100(2):211–219.
132. Ueberricke L, et al. Clinical workflow barriers. Drug Discovery Today. 2023;28(10):103732.
133. U.S. Food and Drug Administration. Office of Combination Products: Guidance Documents. FDA; 2022.
134. Narayan RJ. Reliability testing for MEMS implants. Materials Science and Engineering C. 2015; 55:1–8.
135. O’Shea J, et al. Drug stability under microfabrication stress. Advanced Drug Delivery Reviews. 2022; 182:114105.
136. Ransford B, et al. Security considerations for wireless implants. IEEE Transactions on Biomedical Engineering. 2014;61(5):1686–1694.
137. Stewart CL, et al. Variability in intratumoral conditions affecting implant performance. Advanced Drug Delivery Reviews. 2021; 170:155–170.
138. Cima MJ. Manufacturing constraints for MEMS-based implants. Journal of Controlled Release. 2015; 219:2–8.
139. Devrim B, et al. Impact of sterilization on drug–polymer systems. International Journal of Pharmaceutics. 2020; 587:119676.
140. Amidei J. Ethylene oxide sterilization challenges. Journal of Medical Devices. 2019; 13:030801.
141. Shawgo RS, et al. Quality control in microchip drug devices. Proceedings of the IEEE. 2004;92(1):6–21.
142. Shore RG, et al. Moisture ingress in microdevices. Sensors and Actuators A: Physical. 2019; 295:200–210.
143. Jones D, et al. Reservoir clogging and fouling. ACS Biomaterials Science & Engineering. 2021; 7:1573–1583.
144. Magill ML, et al. Drug–material interactions in sealed reservoirs. Drug Delivery. 2024;31(1):101–117.
145. Bak A, et al. Stability issues of biologics in microreservoirs. Pharmaceutical Research. 2021; 38:13–28.
146. Ye Y, et al. Long-term implant stability studies. Nature Biomedical Engineering. 2017; 1:0014.
147. Baldi A, et al. Cost constraints in MEMS microfabrication. Journal of Micromechanics and Microengineering. 2020; 30:083001.
148. Press RH, et al. Cost-effectiveness of localized oncology therapies. Journal of Clinical Oncology. 2021;39(15):1622–1634.
149. Bruckner T, et al. Economic incentives in implantable drug systems. Health Economics Review. 2019; 9:18.
150. Agarwal A, et al. Healthcare integration challenges for smart implants. Biosensors and Bioelectronics. 2020; 168:112523.
151. Shao H, et al. Zwitterionic biomaterials in implantable devices. Advanced Functional Materials. 2022; 32:2204571.
152. Fan A, et al. Bio-inspired surface engineering. Biomaterials. 2021; 276:121044.
153. Dagdeviren C, et al. Bioresorbable microelectronics. Nature Biomedical Engineering. 2017; 1:0022.
154. Park S, et al. Sensor-integrated smart implants. Science Translational Medicine. 2020;12(534): eaay2431.
155. Lee J, et al. AI-guided drug delivery optimization. Nature Machine Intelligence. 2023; 5:112–124.
156. Tzafriri AR, et al. Multidrug reservoir engineering. Journal of Controlled Release. 2021; 338:707–718.
157. Goldberg MS. Local immunotherapy delivery. Nature Reviews Cancer. 2019; 19:293–307.
158. Varshney D, et al. Stabilizing biologics in microdevices. Pharmaceutics. 2022;14(8):1683.
159. Scheffler K, et al. Immuno-responsive release systems. Advanced Drug Delivery Reviews. 2023; 194:114441.
160. Ho JS, et al. Wireless energy transfer in implants. Proceedings of the IEEE. 2018;106(6):1102–1122.
161. Li Y, et al. Implantable nanogenerators. Nature Communications. 2021; 12:468.
162. Chen R, et al. Miniaturized MEMS therapeutic devices. Microsystems & Nanoengineering. 2022; 8:14.
163. Sahli Costabal F, et al. Digital twins in medicine. Nature Biomedical Engineering. 2020; 4:675–690.
164. Frieboes HB, et al. Computational tumor modeling. Cancer Research. 2022; 82:1205–1217.
165. Shin J, et al. Theranostic smart implants. Advanced Science. 2021; 8:2003674.
166. Jeong JW, et al. Integrated monitoring–therapy systems. Science Advances. 2020;6: eabc9312.
167. Langer R, Traverso G. Localized drug delivery in oncology. Nature Reviews Drug Discovery. 2021; 20:141–142.
168. Jain RK. Personalization of cancer therapy and local drug delivery. Annual Review of Biomedical Engineering. 2022; 24:1–26.
169. Fukumura D, et al. Barriers to clinical translation of implantable drug delivery systems. Cancer Research. 2020; 80:500–511.
170. Cima MJ. Intelligent implants for precision medicine. Nature Biomedical Engineering. 2023; 7:7–9.